Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Andrew Fein has given his Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ potential success with its drug candidate suzetrigine. The drug’s mechanism of action, which ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Revenue surged 67% to $112.2 million, surpassing the consensus estimate of $111.5 million. Arcalyst sales increased by 73% year over year. Kiniksa's net loss of $12.7 million was an improvement ...

Pfizer, facing down a contentious challenge from an activist investor, reported earnings for the third quarter Tuesday that handily beat Wall Street forecasts and led it to boost revenue guidance for ...

It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. Synthesis and characterization of new macrolones — fusions of two antibiotic classes with ...

Derek Wallace was in a dengue-focused intensive care unmet in Thailand in 2009 when he first saw the devastating impact of the disease up close, also known as “breakbone fever.” Facing a shortage of ...

These pockets are decisive in controlling a protein’s cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Candidates should note that DTE Maharashtra has not mentioned any confirmed time for the release of D Pharm CAP Round 1 result. However, the result will be published any time by today evening.